SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

688266

CNE100003RP1

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
53.4 ^CNY	+4.38%		+15.78%	+0.87%

Apr. 19	Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 12	Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials	MT

Suzhou Zelgen Biopharmaceuticals Co., Ltd.(XSSC:688266) added to S&P Global BMI Index

September 18, 2023 at 12:00 am EDT

Latest news about Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
Suzhou Zejing Topical Vitiligo Cream Gets NMPA's Nod for Clinical Trials	Apr. 12	MT
Suzhou Zelgen Biopharmaceuticals Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 23	CI
Zelgen Biopharmaceuticals Grants Yuanda Life Unit Marketing Rights for Recombinant Human Thrombin	Dec. 08	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-27	CI
Zelgen Biopharma’s Phase III Trial of Thyroid Cancer Treatment Yields Positive Results	23-09-19	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(XSSC:688266) added to S&P Global BMI Index	23-09-18	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-25	CI
Zelgen Biopharmaceuticals Gets Nod for China Clinical Trial of Solid Tumor Drug	23-07-31	MT
Apeloa Pharma Forms Strategic Drug Alliance With Zelgen Biopharma	23-06-13	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-21	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that it has received CNY 1.45529 billion in funding	23-04-20	CI
Zelgen Biopharma Gets Nod for Clinical Trials of Tumor Drug	23-04-19	MT
Zelgen Biopharmaceuticals Wins FDA Nod to Trial Lung Cancer Drug	23-04-11	MT
Zelgen Biopharmaceuticals Certified as High-Tech Enterprise in China	23-03-03	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-13	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-18	CI
Zelgen Biopharma Wins Nod to Launch Clinical Trial of Tumor Treatment	22-08-17	MT
Suzhou Zelgen Biopharmaceuticals Co., Ltd.(SHSE:688266) dropped from Shanghai Stock Exchange Health Care Sector Index	22-06-10	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-26	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-23	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. announced that it expects to receive CNY 2.86285 billion in funding	21-11-24	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-26	CI
Suzhou Zelgen Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-20	CI
111 : Partners With Suzhou Zelgen to Develop Liver Cancer Patients Platform in China	21-08-03	MT

Chart Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Duration

Period

Chart Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

More charts

Suzhou Zelgen Biopharmaceuticals Co Ltd is a China-based company mainly engaged in pharmaceutical manufacturing. The Company's main products include pharmaceuticals and pharmaceutical intermediates and raw materials. Its products are mainly applied in the fields of tumors, bleeding and blood diseases, immune inflammatory diseases and hepatobiliary diseases. The Company operates in the domestic market and overseas markets.

Sector

Pharmaceuticals

Calendar

2024-04-29 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Suzhou Zelgen Biopharmaceuticals Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

53.4 CNY

Average target price

64 CNY

Spread / Average Target

+19.85%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SUZHOU ZELGEN BIOPHARMACEUTICALS CO.,LTD.	+0.87%	1.95B
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals